

Medical and Biological Laboratories Co., Ltd., establishes MBL Europe

Medical & Biological Laboratories, Co., Ltd. (Jun Sasaki, President and C.E.O., with Headquarters in Nagoya, Aichi, Japan, hereinafter “MBL”), has announced the opening of our MBL Europe office in Diegem (Mechelen), Belgium as a new liaison/representative office.

MBL Europe represents the third global hub outside of Japan and will strengthen the business segment for personalized medicine and cell therapy fields in Europe. More specifically, MBL Europe will be responsible for customer support for “MEBGENTM RASKET KIT” which can detect both KRAS and NRAS gene mutations and is useful for therapeutic decision prior to anti-EGFR monoclonal antibody therapy to colon cancer. The office will also provide support throughout Europe for our MHC Tetramer product line which can detect antigen-specific T cells directly and quantitatively in immune therapy in fields such as cancer vaccines.

MBL Europe, as strategic hub of MBL Group, will build closer relationship with the European distributors in life science business, and explore new business opportunities in high growth areas including molecular diagnostics, personalized medicine and cell therapy fields.

MBL established MBL International Corporation (Headquarters in Woburn, Massachusetts, U.S.A., hereinafter “MBLI”) as wholly owned company in 1993. MBLI has continued its growth over the years with investments in manufacturing and more recently the opening of a research and development facility in June 2014 to provide high quality, innovative, solutions-based products for life science research and clinical diagnostics in North America, South America, Europe and other countries.

In 2005, MBL opened Beijing B&M Biotech Co., Ltd. (Headquarters in Beijing, China, hereinafter “B&M”), further contributing to advancement of the life science industry in China through its product development, manufacturing and sales of antigens, antibodies and research reagents.

The establishment of MBL Europe will drive the corporate growth strategy as one of the key global hubs together with MBLI and B&M.

[Medical and Biological Laboratories Co., Ltd. (MBL)]

MBL was established as the first antibody manufacturing company in Japan in 1969. The company is currently doing research, development, manufacturing and sales of in vitro diagnostic and research reagents while expanding its business segments into molecular diagnostics and post-translational modification in addition to the immunological field.

For more information, please visit <http://www.mbl.co.jp>.

- Life science research business
MBL provides over 5,000 antibodies, contract manufacturing of custom ordered antibodies, MHC Tetramer, mRNA identification kits, and custom manufacturing of antibodies, oligonucleotides, and artificial genes for the global market.
- Clinical diagnostic business
MBL develops diagnostics for autoimmune diseases, cancers, metabolic disorders, and molecular diagnostics. Leveraging our expertise in immunology, we developed a number of diagnostic reagents designed for difficult to diagnose autoimmune diseases thereby improving the tools available to clinicians.
- Cytology business
MBL provides an innovative system of liquid-based cytology for cervical cancer testing, including reagents for detection of human papillomavirus (HPV) and a brush for collecting cells from the cervix.

[MBL International Corporation (MBLI)]

MBLI, headquartered in Woburn, MA, was established in 1993 as a wholly owned subsidiary of MBL. The company has provided research reagents in life science and clinical diagnostic products manufactured by MBL to the USA and Europe. Through the acquisition of Bion Enterprises, Ltd., in 2008, MBLI expanded its diagnostic portfolio to include immunofluorescence assay products, further strengthening its autoimmune and infectious disease product offering.

MBLI licensed the entire portfolio of MHC tetramer products from Beckman Coulter in 2013, and started selling the products in the USA and Europe. MBLI's sales territories include North America, Europe, Central America, South America, and the Middle East through India. In 2014, MBLI opened a R&D laboratory, and currently evaluates novel product seeds and technologies, does research and development to generate novel research reagents and clinical diagnostics, and acquires new application data for MBL products bound for the U.S. and European countries.

For more information, please visit <http://www.mblintl.com/>.

[Beijing B&M Biotech Co., Ltd. (B&M)]

B&M, a consolidated subsidiary of MBL, was established in Beijing, China in 2005 with the aim of selling MBL's research reagent products, and expanded its activities to develop and manufacture antibodies and clinical diagnostics products.

For more information, please visit <http://www.bio-med.com.cn/>

[CONTACTS]

Medical & Biological Laboratories, Co., Ltd.

KDX Nagoya Sakae Bldg. 10th Floor, 4-5-3 Sakae, Naka-ku, Nagoya, Aichi, 460-0008, Japan

General Affairs Division, E-mail: kouhou@mbi.co.jp